Clinical chemistry forum. , 1994.
Intense scrutiny of the American healthcare paradigm will alter the activities of patients, providers, and payors.
Government reform and marketplace-driven managed care programs create uncertainty.
Quality, access, and cost concerns also drive change.
Quality is conformity to requirements, and specification of requirements creates policy debate.
Variability in utilization creates an accountability chasm between payors and providers that cannot be bridged without understanding the uncertainties in « appropriateness » research.
Quality and access appear secondary to cost.
Cost discussions must differentiate cost and charge.
Inappropriate charge benefit analyses may temporarily benefit a specific organization but are unlikely to create long-term societal benefit.
Multiple transitions have begun, including a shift from disease care to healthcare, provider mentality to consumer mentality, and provider autonomy to collaboration and accountability.
Laboratories will be expected to provide outcomes, not tests ; income will be related to covered lives, not volume, and profit will shift from « piecework and efficiency profit » to « prevention profit. » Only good « outcomes » measurement can reduce uncertainty.
The laboratory contribution to value in care processes remains unclear.
What information is added by each result ?
How can results help prevent the need for future services ?
These are our challenges.
Mots-clés Pascal : Biologie clinique, Examen laboratoire, Exploration, Diagnostic, Pronostic, Qualité, Soin, Diminution coût, Accessibilité, Homme, Prévention
Mots-clés Pascal anglais : Clinical biology, Laboratory investigations, Exploration, Diagnosis, Prognosis, Quality, Care, Cost lowering, Accessibility, Human, Prevention
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0346127
Code Inist : 002B30A11. Création : 01/03/1996.